ABPI Extends Suspension of Astellas UK

08:38 EDT 28 Jun 2017 | CHEManager

The Association of the British Pharmaceutical Industry (ABPI) has suspended Astellas UK’s membership for a further 12 months from Jun. 24 because of several serious breaches of its Code of Practice. The association said recent cases at both Astellas UK and Astellas Pharma Europe have shown “wholly inadequate oversight and control and a lamentable lack of concern for patient safety.”

Original Article: ABPI Extends Suspension of Astellas UK


More From BioPortfolio on "ABPI Extends Suspension of Astellas UK"

Quick Search

Relevant Topic

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...